Drugs / KN052
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05309512 | May 2022 → Nov 2023 | neoplasm | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2023-04-17 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Results 入选Late-Breaking Research！康宁杰瑞KN052临床前数据在2023年AACR年会首次公布 alphamabonc.com ↗
2023年4月17日，中国苏州，康宁杰瑞生物制药(股票代码：9966.HK)宣布，公司自主研发的PD-L1/OX40双抗（研发代号：KN052）临床前研究结果在2023年美国癌症研究协会年会（AACR 2023）Late-Breaking Research首次公布。 |
| 2023-03-15 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Results 康宁杰瑞将于AACR 2023年会上公布PD-L1/OX40双抗KN052临床前研究结果 alphamabonc.com ↗
临床前研究结果表明，KN052具有可接受的药代动力学与安全性，抗肿瘤活性明显强于两个单靶点对照抗体单用及联用。 |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-04-17 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 入选Late-Breaking Research！康宁杰瑞KN052临床前数据在2023年AACR年会首次公布 alphamabonc.com ↗ |
| 2023-03-15 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 康宁杰瑞将于AACR 2023年会上公布PD-L1/OX40双抗KN052临床前研究结果 alphamabonc.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KN052 | “Biological: KN052” NCT05309512 ↗ |
| Route | Intravenous | “once every two or three weeks intravenously” NCT05309512 ↗ |